{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:07:10Z","timestamp":1771373230282,"version":"3.50.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2023,6,30]],"date-time":"2023-06-30T00:00:00Z","timestamp":1688083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,6,30]],"date-time":"2023-06-30T00:00:00Z","timestamp":1688083200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100007013","name":"F. Hoffmann-La Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Universit\u00e4tsklinik M\u00fcnchen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1007\/s12325-023-02565-3","type":"journal-article","created":{"date-parts":[[2023,6,30]],"date-time":"2023-06-30T16:02:10Z","timestamp":1688140930000},"page":"3937-3955","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Efficacy and Safety of Pirfenidone in Advanced Versus Non-Advanced Idiopathic Pulmonary Fibrosis: Post-Hoc Analysis of Six Clinical Studies"],"prefix":"10.1007","volume":"40","clinical-trial-number":[{"clinical-trial-number":"nct01366209","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"J\u00fcrgen","family":"Behr","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6270-1617","authenticated-orcid":false,"given":"Steven D.","family":"Nathan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2804-9511","authenticated-orcid":false,"given":"Ulrich","family":"Costabel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0334-869X","authenticated-orcid":false,"given":"Carlo","family":"Albera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wim A.","family":"Wuyts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1990-6614","authenticated-orcid":false,"given":"Marilyn K.","family":"Glassberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr","given":"Harold","family":"Haller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Alvaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank","family":"Gilberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katerina","family":"Samara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Lancaster","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,6,30]]},"reference":[{"issue":"4","key":"2565_CR1","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1164\/rccm.201006-0894CI","volume":"183","author":"B Ley","year":"2011","unstructured":"Ley B, Collard HR, King TE Jr. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011;183(4):431\u201340.","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"2565_CR2","doi-asserted-by":"publisher","first-page":"00170","DOI":"10.1183\/23120541.00170-2018","volume":"5","author":"J Kaunisto","year":"2019","unstructured":"Kaunisto J, Salomaa E-R, Hodgson U, et al. Demographics and survival of patients with idiopathic pulmonary fibrosis in the FinnishIPF registry. ERJ Open Res. 2019;5(3):00170\u20132018.","journal-title":"ERJ Open Res"},{"issue":"9","key":"2565_CR3","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1164\/rccm.202202-0399ST","volume":"205","author":"G Raghu","year":"2022","unstructured":"Raghu G, Remy-Jardin M, Richeldi L, et al. Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS\/ERS\/JRS\/ALAT clinical practice guideline. Am J Respir Crit Care Med. 2022;205(9):e18\u201347.","journal-title":"Am J Respir Crit Care Med"},{"issue":"132","key":"2565_CR4","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1183\/09059180.00002114","volume":"23","author":"M Kolb","year":"2014","unstructured":"Kolb M, Collard HR. Staging of idiopathic pulmonary fibrosis: past, present and future. Eur Respir Rev. 2014;23(132):220\u20134.","journal-title":"Eur Respir Rev"},{"issue":"12 Pt 1","key":"2565_CR5","doi-asserted-by":"publisher","first-page":"963","DOI":"10.7326\/0003-4819-142-12_Part_1-200506210-00005","volume":"142","author":"FJ Martinez","year":"2005","unstructured":"Martinez FJ, Safrin S, Weycker D, et al. The clinical course of patients with idiopathic pulmonary fibrosis. Ann Intern Med. 2005;142(12 Pt 1):963\u20137.","journal-title":"Ann Intern Med"},{"issue":"4","key":"2565_CR6","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1513\/pats.200601-005TK","volume":"3","author":"DS Kim","year":"2006","unstructured":"Kim DS, Collard HR, King TE Jr. Classification and natural history of the idiopathic interstitial pneumonias. Proc Am Thorac Soc. 2006;3(4):285\u201392.","journal-title":"Proc Am Thorac Soc"},{"issue":"7","key":"2565_CR7","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1164\/rccm.200703-463PP","volume":"176","author":"HR Collard","year":"2007","unstructured":"Collard HR, Moore BB, Flaherty KR, et al. Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2007;176(7):636\u201343.","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"2565_CR8","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1378\/chest.10-2572","volume":"140","author":"SD Nathan","year":"2011","unstructured":"Nathan SD, Shlobin OA, Weir N, et al. Long-term course and prognosis of idiopathic pulmonary fibrosis in the new millennium. Chest. 2011;140(1):221\u20139.","journal-title":"Chest"},{"key":"2565_CR9","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0047-2017","volume":"26","author":"A Caminati","year":"2017","unstructured":"Caminati A, Cassandro R, Torre O, Harari S. Severe idiopathic pulmonary fibrosis: what can be done? Eur Respir Rev. 2017;26: 170047.","journal-title":"Eur Respir Rev"},{"issue":"145","key":"2565_CR10","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0051-2017","volume":"26","author":"H Robbie","year":"2017","unstructured":"Robbie H, Daccord C, Chua F, Devaraj A. Evaluating disease severity in idiopathic pulmonary fibrosis. Eur Respir Rev. 2017;26(145): 170051.","journal-title":"Eur Respir Rev"},{"issue":"1","key":"2565_CR11","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s12890-019-1030-4","volume":"20","author":"L Richeldi","year":"2020","unstructured":"Richeldi L, Kolb M, Jouneau S, et al. Efficacy and safety of nintedanib in patients with advanced idiopathic pulmonary fibrosis. BMC Pulm Med. 2020;20(1):3.","journal-title":"BMC Pulm Med"},{"issue":"18","key":"2565_CR12","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1056\/NEJMoa1811737","volume":"379","author":"M Kolb","year":"2018","unstructured":"Kolb M, Raghu G, Wells AU, et al. INSTAGE investigators: nintedanib plus sildenafil in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2018;379(18):1722\u201331.","journal-title":"N Engl J Med"},{"issue":"10","key":"2565_CR13","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1111\/resp.14116","volume":"26","author":"MT Durheim","year":"2021","unstructured":"Durheim MT, Bendstrup E, Carlson L, et al. Outcomes of patients with advanced idiopathic pulmonary fibrosis treated with nintedanib or pirfenidone in a real-world multicentre cohort. Respirology. 2021;26(10):982\u20138.","journal-title":"Respirology"},{"issue":"3","key":"2565_CR14","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1159\/000492937","volume":"97","author":"H-Y Yoon","year":"2019","unstructured":"Yoon H-Y, Kim DS, Song JW. Efficacy and safety of pirfenidone in advanced idiopathic pulmonary fibrosis. Respiration. 2019;97(3):242\u201351.","journal-title":"Respiration"},{"issue":"9779","key":"2565_CR15","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1016\/S0140-6736(11)60405-4","volume":"377","author":"PW Noble","year":"2011","unstructured":"Noble PW, Albera C, Bradford WZ, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet. 2011;377(9779):1760\u20139.","journal-title":"Lancet"},{"issue":"22","key":"2565_CR16","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1056\/NEJMoa1402582","volume":"370","author":"TE King Jr","year":"2014","unstructured":"King TE Jr, Bradford WZ, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2083\u201392.","journal-title":"N Engl J Med"},{"issue":"22","key":"2565_CR17","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","volume":"370","author":"L Richeldi","year":"2014","unstructured":"Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2071\u201382.","journal-title":"N Engl J Med"},{"issue":"2","key":"2565_CR18","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa030511","volume":"350","author":"G Raghu","year":"2004","unstructured":"Raghu G, Brown KK, Bradford WZ, et al. Idiopathic pulmonary fibrosis study group: a placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2004;350(2):125\u201333.","journal-title":"N Engl J Med"},{"issue":"1","key":"2565_CR19","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1186\/s12931-019-1161-4","volume":"20","author":"TM Maher","year":"2019","unstructured":"Maher TM, Strek ME. Antifibrotic therapy for idiopathic pulmonary fibrosis: time to treat. Respir Res. 2019;20(1):205.","journal-title":"Respir Res"},{"key":"2565_CR20","unstructured":"European Medicines Agency: Summary of Product Characteristics - Esbriet (pirfenidone). 2021. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/esbriet-epar-product-information_en.pdf. Accessed 27 January 2023."},{"key":"2565_CR21","unstructured":"Food and Drug Administration: Highlights of Prescribing Information - OFEV\u00ae. 2022. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/205832Orig1s016lbl.pdf. Accessed 27 January 2023."},{"key":"2565_CR22","unstructured":"Food and Drug Administration: Highlights of Prescribing Information - ESBRIET\u00ae. 2022. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/022535s015,208780s005lbl.pdf. Accessed 27 January 2023."},{"key":"2565_CR23","unstructured":"European Medicines Agency: Summary of Product Characteristics - Ofev (nintedanib). 2021. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/ofev-epar-product-information_en.pdf. Accessed 27 January 2023."},{"key":"2565_CR24","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.rmed.2019.04.016","volume":"153","author":"SD Nathan","year":"2019","unstructured":"Nathan SD, Costabel U, Albera C, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis and more advanced lung function impairment. Respir Med. 2019;153:44\u201351.","journal-title":"Respir Med"},{"issue":"1","key":"2565_CR25","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/S2213-2600(20)30356-8","volume":"9","author":"J Behr","year":"2021","unstructured":"Behr J, Nathan SD, Wuyts WA, et al. Efficacy and safety of sildenafil added to pirfenidone in patients with advanced idiopathic pulmonary fibrosis and risk of pulmonary hypertension: a double-blind, randomised, placebo-controlled, phase 2b trial. Lancet Respir Med. 2021;9(1):85\u201395.","journal-title":"Lancet Respir Med"},{"issue":"1","key":"2565_CR26","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s12931-019-1021-2","volume":"20","author":"U Costabel","year":"2019","unstructured":"Costabel U, Albera C, Glassberg MK, et al. Effect of pirfenidone in patients with more advanced idiopathic pulmonary fibrosis. Respir Res. 2019;20(1):55.","journal-title":"Respir Res"},{"issue":"5","key":"2565_CR27","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1159\/000479976","volume":"94","author":"U Costabel","year":"2017","unstructured":"Costabel U, Albera C, Lancaster LH, et al. An open-label study of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis (RECAP). Respiration. 2017;94(5):408\u201315.","journal-title":"Respiration"},{"issue":"4","key":"2565_CR28","doi-asserted-by":"publisher","first-page":"00084","DOI":"10.1183\/23120541.00084-2018","volume":"4","author":"V Cottin","year":"2018","unstructured":"Cottin V, Koschel D, G\u00fcnther A, et al. Long-term safety of pirfenidone: results of the prospective, observational PASSPORT study. ERJ Open Res. 2018;4(4):00084\u20132018.","journal-title":"ERJ Open Res"},{"issue":"2","key":"2565_CR29","doi-asserted-by":"publisher","first-page":"70","DOI":"10.5582\/irdr.2016.01023","volume":"5","author":"A Agrawal","year":"2016","unstructured":"Agrawal A, Verma I, Shah V, Agarwal A, Sikachi RR. Cardiac manifestations of idiopathic pulmonary fibrosis. Intractable Rare Dis Res. 2016;5(2):70\u20135.","journal-title":"Intractable Rare Dis Res"},{"issue":"4","key":"2565_CR30","doi-asserted-by":"publisher","first-page":"2393","DOI":"10.1378\/chest.128.4.2393","volume":"128","author":"HF Nadrous","year":"2005","unstructured":"Nadrous HF, Pellikka PA, Krowka MJ, et al. Pulmonary hypertension in patients with idiopathic pulmonary fibrosis. Chest. 2005;128(4):2393\u20139.","journal-title":"Chest"},{"issue":"3","key":"2565_CR31","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1378\/chest.129.3.746","volume":"129","author":"CJ Lettieri","year":"2006","unstructured":"Lettieri CJ, Nathan SD, Barnett SD, Ahmad S, Shorr AF. Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis. Chest. 2006;129(3):746\u201352.","journal-title":"Chest"},{"key":"2565_CR32","unstructured":"European Medicines Agency: Summary of Product Characteristics - Esbriet (pirfenidone). 2023. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/esbriet-epar-product-information_en.pdf. Accessed 9 May 2023."}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-023-02565-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-023-02565-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-023-02565-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,15]],"date-time":"2023-08-15T15:18:10Z","timestamp":1692112690000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-023-02565-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,30]]},"references-count":32,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["2565"],"URL":"https:\/\/doi.org\/10.1007\/s12325-023-02565-3","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,30]]},"assertion":[{"value":"6 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}